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IS IT WORTH HAVING A MITRACLIP PROGRAM?
❖ DABIT ARZAMENDI
 Mitral regurgitation is the second most prevalent valvular disease (33.6%)
 More prevalent on patients >75yo (13%)
 Younger patients than EAO, but with more comorbidities:
❖ Myocardial infarction 26.1%
❖ Coronary revascularization13.6%
❖ CKF 4.6%
❖ Heart failure NYHA III-IV 43.3%
Enriquez-Sarano et al. NEJM 2005
IS IT WORTH HAVING A MITRACLIP PROGRAM?
DEGENERATIVE MR (1ª) FUNCTIONAL MR (2ª)
IS IT WORTH HAVING A MITRACLIP PROGRAM?
Iung et al. Curr Prob Cardiol 2007
DEGENERATIVE MR
51.3% DID NOT HAVE SURGERY
IS IT WORTH HAVING A MITRACLIP PROGRAM?
Samad et al. Eur Heart J 2015
FUNCTIONAL MR
90.1% DID NOT HAVE SURGERY
IS IT WORTH HAVING A MITRACLIP PROGRAM?
Goliash et al. Eur Heart J 2017
FUNCTIONAL MR
IS IT WORTH HAVING A MITRACLIP PROGRAM?
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Cid B et al. Rev Esp Cardiol 2018
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• PATIENT SELECTION FOR MITRACLIP: THE KEY TO SUCCESS
CLINICAL AND ANATOMICAL 
SELECTION FOR FUNCTIONAL MR















Neuss Met al. Eur J HF 2013
FUNCTIONAL MR. PATIENT SELECTION
Ledwatchvet al. Clin Res Cardiol 2017
6MWT
FUNCTIONAL MR. PATIENT SELECTION
1 Metze et al.JACC Cardiovasc Intv 2017
FRAILTY
FUNCTIONAL MR. PATIENT SELECTION
OPTIMAL PATIENT
FUNCTIONAL MR. PATIENT SELECTION
• PATIENT SELECTION FOR MITRACLIP: THE KEY TO SUCCESS • DABIT ARZAMENDI





FUNCTIONAL MR. OPTIMAL PATIENT
OPTIMAL RESULT
Stone GW et al. NEJM 2018
NNT=6
≠ PATIENT SELECTION ≠ RESULT
MITRA FR
Obadia et al. NEJM 2018
Obadia et al. NEJM 2018
MiTRA.FR COAPT
n=304 n=614
Severity FMR ESC Guidelines
- ERO >20 mm2 or
- VR>30 mL/beat
Mean ERO 31±10 mm2
Mean LVEDVI 135±35 mL/m2
US Guidelines
- ERO >30 mm2 or
- VR>45 mL/beat
Mean ERO 41±15 mm2
Mean LVEDVI 101±34 mL/m2
GMDT at baseline and 
FU
Allowing adjustment in a ‘real-
world fashion’
Confirmed by CEC ‘maximal
tolerated GMDT’. Few changes
FU




MR≤2+ 12 mo 17% 5%
≠ PATIENT SELECTION ≠ RESULT















Stone et al. TCT 2019
OPTIMAL RESULT
Stone GW et al. NEJM 2018
≠ PATIENT SELECTION ≠ RESULT













FUNCTIONAL MR. OPTIMAL PATIENT
OPTIMAL RESULT
FUNCTIONAL MR. OPTIMAL PATIENT
• PATIENT SELECTION FOR MITRACLIP: THE KEY TO SUCCESS
CLINICAL AND ANATOMICAL 
SELECTION FOR DEGENERATIVE MR
DEGENERATIVE MR. PATIENT SELECTION
Feldman et al. NEJM 2011
EVEREST II RCT
Mauri L et al. JACC 2016
EVEREST II RCT
DEGENERATIVE MR. PATIENT SELECTION
DEGENERATIVE MR. PATIENT SELECTION
SURGICAL RISK SCORES
DEGENERATIVE MR. PATIENT SELECTION
FRAILTY SCORES
DEGENERATIVE MR. PATIENT SELECTION
AVOID CPB
DEGENERATIVE MR. PATIENT SELECTION
Puls et al Eur Heart J 2016





• Mobile lenght of the posterior
leaflet ≥ 10mm
• Coaptation depth < 11mm
• Normal leaflet strengh and 
mobility
• Pathology in segment 1 or 3
• Mild calcification outside the
grip zone of the clip system, 
ring calcification, post‐
annuloplasty
• Mitral valve opening área > 
3cm2 with good residual 
mobility
• Mobile lenght of the posterior 
leaflet 7‐10mm
• Coaptation depth ≥ 11mm
• Leaflet restriction in sístole 
(Carpentier III B)
• Flail width >15mm only with a
large ring width and the
option for multiple clips
• Perforate mitral valve
leaflet or cleft. 


























DMR. EXPERIENCED OF THE OPERATORS
DMR. EXPERIENCED OF THE OPERATORS
DMR. EXPERIENCED OF THE OPERATORS
TTE PRE TTE POST
OTROS DISPOSITIVOS DE 
TÉCNICA EDGE-TO EDGE: 
PASCAL
PACAL. DEVICE DESCRIPTION
 Broad paddles maximise leaflet 
coaptation
 Spacer fills regurgitant orifice 
area
 Manoeuvring in three planes
 Independent leaflet capture
 Spacer and contoured paddles 
reduce stress on leaflets















❖ Mitraclip has shown a reduction in 
mortality (17%) compared to OMT
❖ Predictors of bad prognosis: CF IV, NT-
ProBNP >10000
❖ Predictor of good result: 
disproportionately severe MR
 DMR:
❖ High-risk patients (surgical and frailty)
❖ Good anatomy (A2-P2, no large flail)
Developing a Mitraclip program is worthy: >50% of 
DMR and >90% FMR no surgery 

